Suppr超能文献

奥沙铂和卡铂对大鼠肾功能的影响。

Effect of oxoplatinum and CBDCA on renal functions in rats.

作者信息

Láznícková A, Semecký V, Láznícek M, Zubr V, Koksál J, Kvĕtina J

机构信息

Institute of Experimental Biopharmaceutics, Czechoslovak Academy of Sciences, Hradec Králové.

出版信息

Neoplasma. 1989;36(2):161-9.

PMID:2654665
Abstract

Changes in renal function in rats after single-dose intravenous administration of CBDCA (cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) and oxoplatinum [cis-dichlorodiammine-trans-dihydroxo-platinum(IV)] at a dose of 20 mg/kg were determined and compared. Renal function was monitored by several determinations of effective renal plasma flow (ERPF), glomerular filtration rate (GRF), plasma creatinine and urea and urine beta 2-microglobulin. A significant reduction of ERPF and GRF and a significant increase of plasma creatinine and urea concentration after oxoplatinum treatment were found. On the other hand, no significant changes in renal function parameters were determined after CBDCA. The increase in beta 2-microglobulin amount in rat urine and polyuria persisted until the 14th day after oxoplatinum administration. Histological examination of the kidneys in the experimental animals revealed marked nephrotoxicity changes in the distal tubules after the single-dose administration of oxoplatinum. Administration of CBDCA did not produce pathological renal changes.

摘要

测定并比较了大鼠单次静脉注射剂量为20mg/kg的顺二氨环丁烷二羧酸铂(CBDCA,顺-二氨-1,1-环丁烷二羧酸铂(II))和奥沙铂(顺二氯二氨-反式二羟基铂(IV))后肾功能的变化。通过多次测定有效肾血浆流量(ERPF)、肾小球滤过率(GRF)、血浆肌酐和尿素以及尿β2-微球蛋白来监测肾功能。发现奥沙铂治疗后ERPF和GRF显著降低,血浆肌酐和尿素浓度显著升高。另一方面,CBDCA治疗后未发现肾功能参数有显著变化。大鼠尿液中β2-微球蛋白量的增加和多尿一直持续到奥沙铂给药后第14天。对实验动物肾脏的组织学检查显示,单次注射奥沙铂后远端小管出现明显的肾毒性变化。CBDCA给药未产生病理性肾脏变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验